Enjay, You’ve raised some interesting questio
Post# of 148173
You’ve raised some interesting questions. My opinions to follow
“During the Q&A at the end, there was a discussion about how many doses were used for each patient. Dr. Agresti said they used 2 doses for each patient. Dr. Seethamraju said 4 of their eIND patients got 4 doses. I thought what he said at 46:25 was particularly interesting:”
My response. 4 doses was possible in critical care with EINDs. The 2 doses you referenced were a part of FDA trials where 2 doses were mandated for consistency. We know that repeating doses will help many critical patients or long-haulers. 3-4 doses has been noted for long-haulers. More study will be needed to get to individual precision diagnostics to determine optimal dosing.
Your post again. “In severe illness or in patients who are on home oxygen who are self-monitoring, we have actually sent nurses to administer the medication at home to prevent hospitalization and I think the greatest benefit with the monoclonal that we’re using will be when we administer before the onset or right at the onset of multi-organ dysfunction.”
Is this the first time that administering in a home has been mentioned?”
Me again: No, it isn’t the first time self-administration has been known/discussed. The Sub-Q self administered injection is just like a Diabetes insulin injection and can be 100% self-administered. Seems promising as heck, since other mABs are IV infusion only.
Do you agree?